201 related articles for article (PubMed ID: 11376560)
1. Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer.
Konno H; Abe J; Kaneko T; Baba M; Shoji A; Sunayama K; Kamiya K; Tanaka T; Suzuki S; Nakamura S; Urano T
Jpn J Cancer Res; 2001 May; 92(5):516-23. PubMed ID: 11376560
[TBL] [Abstract][Full Text] [Related]
2. Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer.
Kaneko T; Konno H; Baba M; Tanaka T; Nakamura S
Cancer Sci; 2003 Jan; 94(1):43-9. PubMed ID: 12708473
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression.
Baker EA; Bergin FG; Leaper DJ
Mol Pathol; 2000 Dec; 53(6):307-12. PubMed ID: 11193049
[TBL] [Abstract][Full Text] [Related]
4. Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer.
Konno H; Baba M; Shoji T; Ohta M; Suzuki S; Nakamura S
Clin Exp Metastasis; 2002; 19(6):527-34. PubMed ID: 12405290
[TBL] [Abstract][Full Text] [Related]
5. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
Abe J; Urano T; Konno H; Erhan Y; Tanaka T; Nishino N; Takada A; Nakamura S
Cancer; 1999 Dec; 86(12):2602-11. PubMed ID: 10594855
[TBL] [Abstract][Full Text] [Related]
6. Association of interleukin-8 and plasminogen activator system in the progression of colorectal cancer.
Terada H; Urano T; Konno H
Eur Surg Res; 2005; 37(3):166-72. PubMed ID: 16088182
[TBL] [Abstract][Full Text] [Related]
7. Involvement of vascular endothelial growth factor and urokinase-type plasminogen activator receptor in microvessel invasion in human colorectal cancers.
Nakata S; Ito K; Fujimori M; Shingu K; Kajikawa S; Adachi W; Matsuyama I; Tsuchiya S; Kuwano M; Amano J
Int J Cancer; 1998 Apr; 79(2):179-86. PubMed ID: 9583734
[TBL] [Abstract][Full Text] [Related]
8. Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer.
Nakasaki T; Wada H; Shigemori C; Miki C; Gabazza EC; Nobori T; Nakamura S; Shiku H
Am J Hematol; 2002 Apr; 69(4):247-54. PubMed ID: 11921018
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor expression is reduced in liver metastasis from colorectal cancer and correlates with urokinase-type plasminogen activator.
Berney CR; Yang JL; Fisher RJ; Russell PJ; Crowe PJ
Anticancer Res; 1998; 18(2A):973-7. PubMed ID: 9615749
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
11. Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer.
Ito H; Yonemura Y; Fujita H; Tsuchihara K; Kawamura T; Nojima N; Fujimura T; Nose H; Endo Y; Sasaki T
Virchows Arch; 1996 Feb; 427(5):487-96. PubMed ID: 8624578
[TBL] [Abstract][Full Text] [Related]
12. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
[TBL] [Abstract][Full Text] [Related]
13. Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas.
Fujii T; Obara T; Tanno S; Ura H; Kohgo Y
Hepatogastroenterology; 1999; 46(28):2299-308. PubMed ID: 10521987
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of uPA, uPAR, PAI 1 and PAI 2 tissue expression and plasma PAI 1 level in colorectal carcinoma patients.
Halamkova J; Kiss I; Pavlovsky Z; Jarkovsky J; Tomasek J; Tucek S; Hanakova L; Moulis M; Cech Z; Zavrelova J; Penka M
Hepatogastroenterology; 2011; 58(112):1918-25. PubMed ID: 22234062
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.
Fuessel S; Erdmann K; Taubert H; Lohse-Fischer A; Zastrow S; Meinhardt M; Bluemke K; Hofbauer L; Fornara P; Wullich B; Baretton G; Magdolen V; Wirth MP; Kotzsch M
BMC Cancer; 2014 Dec; 14():974. PubMed ID: 25519168
[TBL] [Abstract][Full Text] [Related]
16. Localization of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, 2 and plasminogen in colon cancer.
Naitoh H; Eguchi Y; Ueyama H; Kodama M; Hattori T
Jpn J Cancer Res; 1995 Jan; 86(1):48-56. PubMed ID: 7737909
[TBL] [Abstract][Full Text] [Related]
17. Correlative studies on uPA mRNA and uPAR mRNA expression with vascular endothelial growth factor, microvessel density, progression and survival time of patients with gastric cancer.
Zhang L; Zhao ZS; Ru GQ; Ma J
World J Gastroenterol; 2006 Jul; 12(25):3970-6. PubMed ID: 16810742
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
Borstnar S; Vrhovec I; Svetic B; Cufer T
Clin Breast Cancer; 2002 Jun; 3(2):138-46. PubMed ID: 12123538
[TBL] [Abstract][Full Text] [Related]
19. Protein markers in colorectal cancer: predictors of liver metastasis.
Berney CR; Fisher RJ; Yang J; Russell PJ; Crowe PJ
Ann Surg; 1999 Aug; 230(2):179-84. PubMed ID: 10450731
[TBL] [Abstract][Full Text] [Related]
20. Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness.
Buø L; Meling GI; Karlsrud TS; Johansen HT; Aasen AO
Hum Pathol; 1995 Oct; 26(10):1133-8. PubMed ID: 7557947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]